Advertisement

Topics

Bacterial Conjunctivitis - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Bacterial Conjunctivitis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 53-page report is available in PDF from $2000.

Bacterial Conjunctivitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bacterial Conjunctivitis - Pipeline Review, H1 2015’, provides an overview of the Bacterial Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bacterial Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bacterial Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bacterial Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Conjunctivitis Overview 6
Therapeutics Development 7
Pipeline Products for Bacterial Conjunctivitis - Overview 7
Pipeline Products for Bacterial Conjunctivitis - Comparative Analysis 8
Bacterial Conjunctivitis - Therapeutics under Development by Companies 9
Bacterial Conjunctivitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Bacterial Conjunctivitis - Products under Development by Companies 13
Bacterial Conjunctivitis - Companies Involved in Therapeutics Development 14
Cellceutix Corporation 14
China Grand Wuhan General Pharmaceutical Research Institute 15
Daiichi Sankyo Company, Limited 16
InSite Vision Incorporated 17
NovaBay Pharmaceuticals, Inc. 18
Ocular Therapeutix, Inc. 19
Bacterial Conjunctivitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
auriclosene - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
brilacidin tetrahydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ISV-405 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
levofloxacin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
moxifloxacin hydrochloride SR - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NVC-638 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NVC-704 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NVC-727 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
XY-0911AQ2 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Bacterial Conjunctivitis - Recent Pipeline Updates 39
Bacterial Conjunctivitis - Dormant Projects 50
Bacterial Conjunctivitis - Product Development Milestones 51
Featured News & Press Releases 51
Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US 51
Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops 51
Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops 51
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

For more information open Bacterial Conjunctivitis - Pipeline Review, H1 2015.

SKU: GMDHC6631IDB

Original Article: Bacterial Conjunctivitis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Bacterial Conjunctivitis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...